← All trials
NCT06026410
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2023
- Primary completion
- Jan 31, 2027
- Completion date
- Apr 30, 2027
- First posted
- Sep 7, 2023
- Last posted
- Nov 22, 2023
- Enrollment
- 270
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kura Oncology, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.